大剂量静脉输注甲钴胺预防硼体佐米治疗诱发的多发性骨髓瘤患者周围神经病的效果
发布时间：2018-08-19 13:15
【摘要】：目的:观察大剂量静脉输注甲钴胺预防硼替佐米治疗多发性骨髓瘤(MM)引起的周围神经病(bortezomib-induced peripheral neuropathy,BIPN)的临床效果及安全性。方法:采用单中心随机对照临床研究2012年7月至2016年5月我中心65例新诊断的MM患者,将他们分为2组,其中治疗组27例,采用静脉输注大剂量甲钴胺预防BIPN;对照组38例,未接受任何预防BIPN的药物。观察2组患者BIPN的发生率及其严重度并分析疗效、生存率及药物的不良反应。结果:治疗组和对照组患者年龄和性别比例均无统计学差异(P0.05)。治疗组BIPN发生率(29.63%)明显低于对照组(55.26%)(χ~2=4.197,P0.05),治疗组Ⅱ和Ⅲ级以上BIPN发生率分别为18.52%和3.71%,均明显低于较对照组(47.37%,21.05%)(χ~2=5.746,P0.05;χ~2=3.983,P0.05);2组因Ⅲ级及Ⅲ级以上程度BIPN导致未完成5个疗程Vel治疗的分析结果显示:治疗组为3.71%,低于对照组15.79%,但无明显统计学差异(χ~2=2.714,P0.05)。治疗组和对照组的总有效率分别为77.78%和73.68%(P0.05)。治疗组和对照组的PFS和OS均无统计学差异(P0.05)。静脉输注大剂量甲钴胺的安全性的分析结果显示,治疗组3.71%患者出现轻度皮疹,无其它毒副作用发生。结论:大剂量静脉输注甲钴胺能有效预防BIPN发生,或减轻其严重程度,具有良好安全性。
[Abstract]:Objective: to observe the efficacy and safety of high dose intravenously infusion of mecobalamin in the treatment of bortezomib-induced peripheral neuropathy-induced bortezomib-induced peripheral neuropathy (bortezomib-induced peripheral) caused by multiple myeloma (MM). Methods: from July 2012 to May 2016, 65 newly diagnosed MM patients in our center were randomly divided into two groups: treatment group (n = 27) and control group (n = 38). No medication for the prevention of BIPN was accepted. The incidence and severity of BIPN were observed and the curative effect, survival rate and adverse drug reaction were analyzed. Results: there was no significant difference in age and sex ratio between treatment group and control group (P0.05). The incidence of BIPN in the treatment group (29.63%) was significantly lower than that in the control group (55.26%) (蠂 ~ (2 / 2) / 4.197). The incidence of BIPN in the treatment group was 18.52% and 3.71% respectively, which was significantly lower than that in the control group (47.37%, 21.05%) (蠂 ~ (25.746) P 0.05; 蠂 ~ (23) 983). The results showed that the value of the treatment group was 3.71, lower than that of the control group 15.79, but there was no significant difference (蠂 2, 2.714, P 0.05). The total effective rates of treatment group and control group were 77.78% and 73.68% respectively (P0.05). There was no significant difference in PFS and OS between the treatment group and the control group (P0.05). The results of safety analysis showed that 3.71% of the patients in the treatment group had mild rash and no other side effects. Conclusion: high dose intravenous infusion of mecobalamin can effectively prevent or reduce the severity of BIPN, and has good safety.
【作者单位】： 天津医科大学;天津医科大学总医院血液科;
【基金】：天津市自然科学基金(12JCZDJC21500、14JCYBJC25400) 天津市抗癌重大专项攻关计划(12ZCDZSY18000) 天津医科大学基金(2010ky20)
【分类号】：R733.3
本文编号：2191758
[Abstract]:Objective: to observe the efficacy and safety of high dose intravenously infusion of mecobalamin in the treatment of bortezomib-induced peripheral neuropathy-induced bortezomib-induced peripheral neuropathy (bortezomib-induced peripheral) caused by multiple myeloma (MM). Methods: from July 2012 to May 2016, 65 newly diagnosed MM patients in our center were randomly divided into two groups: treatment group (n = 27) and control group (n = 38). No medication for the prevention of BIPN was accepted. The incidence and severity of BIPN were observed and the curative effect, survival rate and adverse drug reaction were analyzed. Results: there was no significant difference in age and sex ratio between treatment group and control group (P0.05). The incidence of BIPN in the treatment group (29.63%) was significantly lower than that in the control group (55.26%) (蠂 ~ (2 / 2) / 4.197). The incidence of BIPN in the treatment group was 18.52% and 3.71% respectively, which was significantly lower than that in the control group (47.37%, 21.05%) (蠂 ~ (25.746) P 0.05; 蠂 ~ (23) 983). The results showed that the value of the treatment group was 3.71, lower than that of the control group 15.79, but there was no significant difference (蠂 2, 2.714, P 0.05). The total effective rates of treatment group and control group were 77.78% and 73.68% respectively (P0.05). There was no significant difference in PFS and OS between the treatment group and the control group (P0.05). The results of safety analysis showed that 3.71% of the patients in the treatment group had mild rash and no other side effects. Conclusion: high dose intravenous infusion of mecobalamin can effectively prevent or reduce the severity of BIPN, and has good safety.
【作者单位】： 天津医科大学;天津医科大学总医院血液科;
【基金】：天津市自然科学基金(12JCZDJC21500、14JCYBJC25400) 天津市抗癌重大专项攻关计划(12ZCDZSY18000) 天津医科大学基金(2010ky20)
【分类号】：R733.3
【相似文献】
相关期刊论文 前1条
1 陈婵娟;陈昌南;潘岐作;张呈;谢峰;;甲钴胺预防紫杉醇神经毒性疗效观察[J];中国热带医学;2014年04期
，本文编号：2191758
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2191758.html
